Biogen Idec has signed a definitive merger agreement for the acquisition of Conforma Therapeutics. Conforma is focused on the discovery and development of drugs that inhibit heat shock protein 90 (HSP90) molecules, which are involved in supporting the growth of cancer cells across a range of tumor types, and which also play a role in tumor resistance to a number of leading cancer therapies. The company has advanced two compounds into Phase I trials: CNF1010, a proprietary form of the geldanamyc...